Loading company
Anavex Life Sciences Corp.
AVXL · Nasdaq · ·
$2.38+1.3%Sep 29 close
- 1M
- -17.1%
- 6M
- -23.2%
- 1Y
- -73.6%
- 5Y
- -87.6%
AVXL · Nasdaq · ·
$2.38+1.3%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | $7.8M | -$13.2M | +159.08% |
| Profit per share | $0.08 | -$0.16 | +150.00% |
| Free Cash Flow | -$1.4M | -$960K | -48.99% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Anavex Life Sciences Corp. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical stage biopharmaceutical company engaged in the development of novel therapeutics for the treatment of central nervous system (“CNS”) diseases with high unmet medical need. Further information is available at www.anavex.com .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Anavex Life Sciences Corp.’s Item 2.02 8-K filed August 25, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.